Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00439569 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III
A Phase 1 study, sponsored by Westat.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00439569 is a Phase 1 study that was terminated before completion, run by Westat. The registered enrollment target is 9 participants.
The verdict
NCT00439569, a Phase 1 study, was terminated before completion, sponsored by Westat.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to identify the maximum tolerated dosage of sodium phenylbutyrate in children with spinal muscular atrophy types II or III; and to determine if the drug has an effect on SMN mRNA and protein levels.
Interventions
- DRUG sodium phenylbutyrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00439569
The ClinicalTrials.gov registry entry for NCT00439569 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Westat, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sodium phenylbutyrate is the first listed.
NCT00439569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00439569 about?
NCT00439569 is a clinical study titled "Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III". The purpose of this study is to identify the maximum tolerated dosage of sodium phenylbutyrate in children with spinal muscular atrophy types II or III; and to determine if the drug has an effect on SMN mRNA and protein levels.
What is the current status of trial NCT00439569?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-01. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00439569?
The interventions under investigation include: sodium phenylbutyrate (DRUG).
Who is sponsoring clinical trial NCT00439569?
This trial is sponsored by Westat, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.